Press Releases Press Releases Year None20192018 November 5, 2019 Stoke Therapeutics to Present at Upcoming Investor Conferences in November October 16, 2019 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources September 30, 2019 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference September 11, 2019 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome August 14, 2019 Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update August 6, 2019 Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome August 1, 2019 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference June 21, 2019 Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares June 18, 2019 Stoke Therapeutics Announces Pricing of Initial Public Offering Pagination Current page 1 Page 2 Next page next › Last page last » Toolkit Print Page Email Alerts Contact IR FAQ
Press Releases Year None20192018 November 5, 2019 Stoke Therapeutics to Present at Upcoming Investor Conferences in November October 16, 2019 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources September 30, 2019 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference September 11, 2019 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome August 14, 2019 Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update August 6, 2019 Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome August 1, 2019 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference June 21, 2019 Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares June 18, 2019 Stoke Therapeutics Announces Pricing of Initial Public Offering Pagination Current page 1 Page 2 Next page next › Last page last »
October 16, 2019 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources
August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome
August 14, 2019 Stoke Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
August 6, 2019 Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
June 21, 2019 Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares